When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
GOSS - Novartis bails on asthma med fevipiprant after study failures
Gossamer Bio Inc.
Novartis (NYSE:NVS) has decided to stop development of fevipiprant after a series of unsuccessful clinical trials. In October, the DP2 antagonist failed improve lung function in two Phase 3 studies in patients with moderate asthma.
More news on: Novartis AG, Gossamer Bio, Inc., Healthcare stocks news,